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ABSTRACT
Systemic and localized scleroderma are difficult
to manage diseases with no accepted gold
standard of therapy to date. Phototherapeutic
modalities for scleroderma show promise.
A PubMed search of information on
phototherapy for scleroderma was conducted.
The information was classified into effects on
pathogenesis and clinical outcomes. Studies on
photopheresis were excluded. There were no
randomized, double-blind, placebo-controlled
studies, and only three controlled studies. The
vast majority of identified studies evaluated
ultraviolet A1 (UVA1) phototherapy. More
rigorous studies are needed to evaluate
phototherapy in the treatment of scleroderma.
Based on the limited studies available, 20–50 J/
cm2 of UVA1 therapy 3–4 times a week for 30
treatments is recommended.




Scleroderma is a chronic autoimmune disease
associated with cutaneous, joint, and internal
organ involvement. Cutaneous scleroderma is
characterized by enhanced fibroblast activity
leading to hypertrophic dermal collagen. There
are localized and systemic forms of scleroderma.
The localized forms include morphea and linear
scleroderma. Localized scleroderma has a better
prognosis and does not involve internal organs.
There are currently no curative treatments for
scleroderma. Current treatments include
immunosuppressants; intralesional, topical,
and oral steroids; topical vitamin D; and
phototherapy. This review serves to provide
insight into the use of phototherapy in the
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management of scleroderma. This article is
based on previously conducted studies and
does not involve any new studies of human or




Phototherapy modalities utilize specific
wavelengths of the electromagnetic spectrum
to disrupt the dysfunctional and pathologic
tissue that has developed in some patients with
skin disease. Various phototherapy modalities
possess anti-inflammatory effects [1]. The
longer the wavelength of phototherapy, the
deeper in the dermis it penetrates [2]. Current
phototherapeutic modalities being used for
dermatoses include broadband ultraviolet B
(UVB 290–320 nm), narrowband UVB
(311–313 nm), excimer laser (308 nm),
ultraviolet A (UVA 320–400 nm), ultraviolet A1






A common theory behind the mechanism of
phototherapy in scleroderma is that light is
converted to chemical energy resulting in the
increase of reactive oxygen species or singlet
oxygen production, which can modulate the
expression of cytokines [3, 4]. Ultraviolet
radiation includes UVA and UVB therapy, with
UVA1 studied the most. UVA1 can have an
output categorized as low (10–30 J/cm2),
moderate (40–70 J/cm2), or high (up to 130 J/
cm2).
UVA1 radiation increases collagenase [also
known as the matrix metalloproteinase-1
(MMP-1)] gene, mRNA, and protein expression
by fibroblasts [5–9]. In mice models, UVA1
radiation reduces fibroblast proliferation in a
dose-dependent fashion [10, 11]. Additionally,
UVA1 radiation administered three times a
week showed decreased hydroxyproline and
collagen levels in a dose-dependent fashion
[11]. The quality of the collagen is altered after
UVA1 therapy, as collagen appears less dense
and smoother compared to before treatment
[12]. Decorin (a proteoglycan component of
connective tissue) mRNA levels are lower in
lesional scleroderma versus non-lesional skin,
and decorin levels are increased after UVA1
phototherapy [13]. Transforming growth factor
beta (TGF-b) protein levels (TGF-b is profibrotic)
are inversely correlated with decorin levels. On
the other hand, another study showed that after
UVA1 phototherapy, decorin was decreased in
the upper to middle dermis, although decorin
slightly increased in the papillary dermis [14].
In patients, UVA has been shown to reduce
collagen I, collagen III, and TGF-b and increase
interferon-c [9]. UVB radiation increases alpha
melanocyte-stimulating hormone (a-MSH)
receptor synthesis in keratinocytes and
melanocytes [15]. Human fibroblast dermal
cultures treated with a-MSH demonstrated an
increase in MMP-1 mRNA, indicating that
a-MSH may be one of UVB’s mediators of
anti-fibrosis [16].
The source of the mediators that contribute
to the reduction in sclerosis comes mostly from
the dermis. Subsequently, certain parts of the
dermis may be impacted more than others. An
image analyzer showed a greater reduction in
collagen fibers in the upper and middle dermis
and less reduction in the lower dermis [12]. In
18 patients treated with UVA1, the MMP-1 level
was higher in the papillary layers and lower in
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the reticular layers [17]. The anti-fibrotic effects
of phototherapy may not come exclusively
from the dermis. Samples taken 18 h after the
final UVA1 treatment in a set of patients
showed an increase in interstitial collagenase
in the upper layer of keratinocytes,
melanocytes, and endothelial cells [5].
Evidence supports the regimen of multiple
UVA1 therapy sessions a week. The
anti-sclerotic effects of a single exposure of
UVA1 effects are typically seen to last less than
1 week. In human skin, mRNAs of type I and III
procollagen were decreased and MMP-3 was
increased after 3 days of a single UVA1 dose
[18]. MMP-1 and MMP-3 were upregulated for 3
to 5 days, while procollagen levels were
suppressed for at least 7 days [18]. In this small
study, anti-fibrotic responses became refractory
to multiple UVA1 exposures over the course of
1 week, as repeated exposures weekly showed
no reduction in type I procollagen levels [18].
UVA1 therapy can have an
immunomodulatory effect on lesional skin.
UVA1 can reduce inflammation in the dermis
[12]. UVA1 causes apoptosis of T-cells [19].
Patients with morphea exposed to UVA1 with
a dose of 30 J/cm2 and a cumulative dose of
900 J/cm2 were found to have an increase in
CD34? dendritic cells [20]. Human beta
defensin[s] (HBD), interleukin (IL)-6 and IL-8
are downregulated in patients with localized
scleroderma treated with UVA1 phototherapy
[6]. On the other hand, another study showed
that UVA1 induces MMP-1 through a
mechanism involving IL-1 and IL-6 [21].
UVA1 radiation may induce oxidative stress,
as evidenced by an increase in UVA1-induced
heme oxygenase-1 in fibroblasts [7].
Glutathione was lower in systemic sclerosis
(SSc) fibroblasts than control samples, but
glutathione was increased and became
equivalent between normal and SSc fibroblasts
after in vitro irradiation with UVA1 [8]. Thus,
the SSc fibroblasts may be more susceptible to
phototherapy-induced oxidative stress than
normal fibroblasts [8]. Additionally, heme
oxygenase-1 may reduce fibrotic conditions via
TGF-b [22]. UVA1 may play a role in
angiogenesis. In patients exposed to UVA1
phototherapy for 14 weeks, there was an
increase in CD34? cells and an increase in
vascular endothelial growth factor (VEGF) [23].
The neuroendocrine system may be involved, as
UVA1 therapy decreases dermal expression of
neuron-specific enolase, which correlated with
softening of skin lesions in patients with SSc
with acral lesions [24].
UVB phototherapy results in DNA damage,
forming cyclobutane pyrimidine dimers
between nucleotides [25]. There is evidence
that broadband UVB can induce interstitial
collagenase, stromelysin, and IL-6 [26]. There
may be an interplay between these enzymes
and cytokines [26]. Broadband UVB radiation
can induce production of MMP-1 in
fibroblasts [27]. When keratinocytes are
exposed to UVB, there is an increase in IL-1a
and IL-6, which induced MMP-1 [27]. Human
keratinocytes cultured in a model system
exposed to 300 J/cm2 of broadband UVB
produced IL-1a, IL-6, and tumor necrosis
factor alpha (TNF-a) [28].
PUVA is another modality that can be used
for scleroderma. PUVA can lead to apoptosis of
T-cells in the dermis [19]. In patients with SSc
treated with PUVA, the majority of patients
experienced an increase in circulating TNF-a
levels, E-selectin, and vascular cell adhesion
molecule (VCAM). In the majority of patients,
there was a reduction in VEGF and TGF-b [29].
On the other hand, in patients with morphea
treated with PUVA, there was a fall in serum
VCAM molecules and an increase in TNF-a in
most patients [30]. In a bleomycin-induced
Dermatol Ther (Heidelb) (2016) 6:519–553 521
scleroderma rat model, PUVA treatment
reduced dermal thickness and hydroxyproline
content and downregulated expression of type I
and III collagen genes [10]. In one patient with
SSc, treatment with oral PUVA therapy three
times a week for 4 weeks resulted in loosening
of collagen, reduction in edema, and decreased
CD34? cells [31]. Bath PUVA treatment has
effects on collagen cross-links in human skin
samples of scleroderma, reducing
hydroxylysylpyridinoline and lysylpyridinoline
[32]. UVA1 treatment affected collagen fibrils
mostly in the upper reticular dermis [33],
whereas PUVA affected collagen fibrils in the
upper and middle reticular layers [33].
Additionally, collagen fibrils decreased and
new fibrils developed, suggesting UVA1 and
PUVA phototherapies’ impact on sclerotic
lesions occurs via collagen degradation and
new collagen synthesis [33].
Other modalities have also been studied.
Photodynamic therapy (PDT) with
5-aminolevulinic acid (5-ALA) treatment of
scleroderma fibroblasts increased MMP-1 and
MMP-3, and there was a decrease in collagen
type 1 mRNA as early as 6 h after treatment [34].
Keratinocytes exposed to PDT with 5-ALA had
an increase in IL-1a and TNF-a [35]. In
fibroblasts that were incubated with
keratinocytes pre-exposed to PDT with 5-ALA,
there was an increase in MMP-1 and MMP-3;
Karrer et al. [35] subsequently suggested
paracrine signaling between the phototherapy
exposed keratinocytes and the fibroblasts.
Furthermore, an IL-1 antagonist reversed the
induction of MMP-1 and MMP-3 in fibroblasts
[35]. Blue light up to 453 nm is toxic to cultured
T cells, causing apoptosis, but was nontoxic for
other skin cell types [36].
THE USE OF PHOTOTHERAPY
IN DERMATOLOGY
Phototherapy is commonly used for many
dermatoses, but there is less usage for
scleroderma. Of 653 patients using
phototherapy in a Brazilian clinic, 11 were
there for scleroderma treatment [37]. In a
multi-center response from 155 British
pediatric physicians, PUVA was the most
popular phototherapy modality (38%),
followed by narrowband UVB (23%) and UVA1
(16%) for morphea [38]. These same clinicians
were also asked what would be the best
treatment option overall in their opinion for
active morphea: 17% responded phototherapy
and about 2/3 of these responses were for UVA1,
which was only accessible to 27% of
respondents [38]. Phototherapy for adult skin
disorders is almost exclusively provided by
dermatologists [39]. In a survey of physicians
treating juvenile localized scleroderma in the
UK, 19 of 28 pediatric dermatologists used UV
therapy, whereas 0 of 10 pediatric
rheumatologists used UV therapy [40]. A
self-reported survey of dermatologists and
rheumatologists revealed that 20% of
dermatologists (n = 40) and 10.6% of pediatric




A PubMed search was performed with the
Boolean search terms ‘scleroderma’ OR
‘morphea’ OR ‘crest’ AND ‘phototherapy.’ The
search years yielded were from 1978 to 2016.
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Clinical articles in a non-English language were
excluded.
UVA1
UV therapy for patients with localized
scleroderma was introduced as PUVA in 1994
[42]. In 1995, Kerscher et al. [43] reported that
low-dose UVA1 phototherapy could be used in
linear scleroderma. It is unclear whether there is
an association between initial skin disease
duration and response to UVA1 therapy. A
study of ten patients with sclerodermic lesions
determined that there was no correlation
between disease duration and clinical response
with UVA1 [44].
Table 1 lists the clinical reports of UVA10s
efficacy in scleroderma or morphea. It is
important to note that covered sclerotic
lesions show less improvement after UVA1
therapy [45]. Ultrasound is an objective
measure used to assess skin thickness in
several UVA studies. Fourteen patients with
localized scleroderma treated with UVA1 were
evaluated with a 13-MHz ultrasound, and
dermal thickness was increased before therapy
and decreased from 3.11 ± 1.54 to 2.26 ± 0.86
[46]. Other studies have also supported a
correlation of a decrease in dermal thickness
when treating with UVA1 therapy [47].
Skin darkness or darkening likely has no
effect on UVA1’s efficacy. Forty-seven patients
with morphea and 35 with SSc treated with
UVA1 phototherapy were analyzed to see
whether Fitzpatrick skin type makes an impact
on the outcome, with the result being that
medium- to high-dose UVA1 had similar
efficacy in skin types I–V [48]. There was also
no correlation noted for Fitzpatrick skin type
and cumulative dose or clinical improvement.
The current evidence suggests that UVA1
effects are dose-related. In an observational
report for patients with SSc who completed at
least ten treatments, 20% of those treated with
low-dose (20–40 J/cm2) UVA1 (n = 5), 83.3% of
those treated with medium-dose ([40–80 J/cm2)
UVA1 (n = 6), and 100% of those treated with
high-dose ([80–120 J/cm2) UVA1 (n = 5)
reported improvement [49]. A 14-patient study
showed a 70-J/cm2 dose was more effective in
treating localized scleroderma lesions than a
20 J/cm2 dose [45]. In six patients with localized
scleroderma treated two to three times a week,
three patients experienced complete remission
[50]. Two of the three received high-dose 100 J
UVA1 therapy, of which one of them received
67 treatments and relapsed after 6 months,
compared to one patient which received
low-dose UVA1 twice weekly for 6 weeks for a
total of 39 irradiations and did not relapse after
84-month follow up [50]. A broadband UVA
trial examined 63 patients with morphea and 15
patients treated with UVA1 5, 10, or 20 J/cm2
with cumulative doses of 100, 200, and 400 J/
cm2, respectively [51]. Clinical improvement
was observed in all patients, but there was no
comparable difference between the UVA doses.
Long-term outcome of UVA1 therapy is
unclear. In a cohort study of 37 patients with
morphea with positive clinical benefits from
UVA1 treatment 44.5% recurred at 2 years, and
48.4% recurred at 3 years [52]. There was no
difference between medium- (60–90 J/cm2) and
high-dose ([90 J/cm2) UVA1 phototherapy with
respect to recurrence. There was a 1.15-times
higher chance of disease recurrence for an
increment of 1 year in duration of morphea
prior to UVA1 treatment [52].
Broadband UVA
Twelve patients with morphea were treated
with low-dose (20 J/cm2) broadband UVA 3
times a week for a total of 20 sessions [12].
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Improved softness of skin lesions assessed by
palpation was reported as early as three
treatments and as late as ten treatments.
Longer standing lesions did not respond as
well as therapy. As a control, some lesions in the
same patients were covered to prevent UVA1
exposure during treatment, and less softening
was reported in these covered lesions. After a
1-year follow-up, only two patients reported a
reappearance of lesions. Lesions on skin creases
or over joints did not respond as well to therapy
[12].
PUVA
A 15-year-old male with scleroderma with
indurated patches on the trunk and
joint restrictions was recalcitrant to
hydroxychloroquine, prednisolone, and
methotrexate [53]. PUVA at a dose of
0.6 mg/kg twice weekly was subsequently
added for 20 sessions over 10 weeks at a
cumulative dose of 25.4 J/cm2. Methotrexate
was subsequently administered for 7 months.
After this period, he was able to make a full
fist and increase to a normal range of motion
in the ankles; his skin was less indurated and
has maintained clinical stability for 2 years
[53]. Table 1 lists additional PUVA treatment
studies in scleroderma/morphea. PUVA’s
effects may be due to local effects rather
than systemic effects, as Kerscher et al. [54]
noted that residual sclerotic lesions remained
in patients in areas hidden from UVA
exposure such as parts of the elbow in
patients undergoing PUVA.
UVB
A 43-year-old female with radiation-induced
morphea was given acitretin daily and UVB
three times a week [55]. Two months
afterwards there was less induration of her
plaque, decreased tenderness, and improved
range of motion of the left arm [55]. Eleven
patients that underwent phototherapy
treatment (seven treated with PUVA and four
treated with narrowband UVB) for an average
of ten sessions experienced a 48%
improvement of their localized scleroderma
as indicated by a clinical pinching test [56].
Additionally, the ultrasound examination
showed a dermal thickness reduction ranging
from 20% to 100% [56]. There was no
correlation between the type of
phototherapy and clinical response rate [56].
Additional studies on UVB therapies are
included in Table 1.
Targeted Phototherapy
Targeted phototherapy is a modality that spares
non-lesional skin and is able to deliver a higher
fluence. A patient with limited scleroderma and
elbow mobility restrictions was treated 2–3
times a week for 13 weeks with 940-nm
low-level light therapy with millisecond
pulsing and continuous wave modes. Using a
sequential pulsing dose on one elbow and
continuous wave mode on the other, better
results were seen with the pulsing mode
showing improvement in skin thickness [57].
Five patients with a total of 11 plaques were
treated with a 308-nm monochromatic excimer
laser for 4 weeks at a power density of 48 mW/
cm2 with a maximum irradiation area of
512 cm2 [58]. The mean number of treatments
was seven, and the dose per session was 1.5 J/
cm2. The mean total dose was 10 J/cm2. After 4
weeks, 3 out of 5 patients experienced marked
improvement with residual hyperpigmentation
[58].
A 27-year-old Hispanic female had a
contracture of her knee with sclerotic bands
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on her left lower leg, ankle, and foot that were
recalcitrant to methotrexate, UVA1, topical
calcipotriene, intralesional triamcinolone
acetonide, and physical therapy [59]. The
patient was treated with a single treatment of
10.6 lm carbon dioxide laser with a 50 J/cm2
pulse energy, while remaining on methotrexate
and topical agents [59]. After 1 week, she
experienced an increase in range of motion.
After 4 months of follow-up, there was
softening of her contracture, and she regained
full plantar flexion of her left foot. After a 1-year
follow-up, she maintained a full range of
motion [59].
Four patients with microstomia and SSc were
treated with intense pulsed light. 530–570 mm,
11–14 J/cm2; 10–14 pulse durations was used for
the patients every 4 weeks [60]. Patients were
followed for 4 months. Three patients
experienced an increased interincisal distance
of *1 mm per treatment [60]. One patient did
not have improved interincisal distance, but did
note activities of daily living became easier. One
patient did report recurrence of the stiffness
after 3 weeks [60]. Table 1 lists additional
reports of targeted phototherapy.
Photodynamic Therapy
In six patients, 20% 5-ALA was applied under
occlusion to areas of morphea for 5 h. A band
width of 570–670 nm, peak 635-nm light was
given. A dose of 25 J/cm2 was given for a
total of six weekly treatments. In four of the
patients there was clinical improvement as
determined by skin scoring, although only
one of these patients showed histologic
evidence of improvement. The side effects
patients reported included burning
sensation, dryness, erythema, pigmentation,
and pruritus [61]. Table 1 lists an additional
study.
DISCUSSION
There are mostly care reports of UVA1, UVB,
PUVA (bath and topical), and targeted
phototherapies in cases of scleroderma. UVA1
appears to be the most efficacious, but it is also
the most studied. There are not many studies on
high-dose UVA1, and this needs to be
investigated further to assess the optimal dose
of UVA to use in scleroderma. Additionally,
longer term studies are needed to study the
long-term outcome and safety of these
treatments. A similar literature review study
delineated UVA and PUVA’s efficacy and safety
in the context of SSc, localized scleroderma,
extragenital lichen sclerosus et atrophicus,
sclerodermoid graft-versus-host disease, lupus
erythematosus, and other rare sclerotic diseases
[62]. This review also asserts that there need to
be more rigorous studies to help establish a
guide for UVA’s indications as well as its efficacy
compared to other conventional medical
therapies [62].
Based on the studies available, a reasonable
regimen is UVA1 therapy 20–50 J/cm2 3–4 times
a week for a total of 30 treatments. There were
no double-blind, placebo-controlled trials
available, and only three controlled trials.
Adverse effects thus far do not correlate with
the intensity of therapy. The side effects noted
in scleroderma phototherapy include fatigue, a
burning sensation, hyperpigmentation,
pruritus, erythema, edema, headaches,
gastrointestinal upset, and joint and muscle
pain. Additionally, one patient undergoing
UVA1 phototherapy for disseminated morphea
developed bullous pemphigoid after 29
treatments [63]. The long-term effects of UVA1
on patients have not reported skin cancer [64].
Phototherapy should be safe in pregnancy [65]
although folate may need to be supplemented
as reports show that UVB and solar UV radiation
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may cause photodegradation [66, 67]. Multiple
treatments, as well as limited availability of
in-office phototherapy, are barriers to
treatment. In a review by Bielsa Marsol [68], it
was pointed out that most of the studies for
UVA1 therapy were performed in countries
where patients are predominantly Fitzpatrick
types I–III, although, as noted earlier, the
Fitzpatrick skin type thus far has not been
shown to have an impact on therapy.
Phototherapy may not be as useful for
sclerotic diseases that affect structures deeper
than the dermis.
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